We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Cincinnati Sub-Zero

Download Mobile App




Baxter Acquires Cheetah Medical to Expand Specialized Patient Portfolio

By Labmedica International staff writers
Posted on 18 Sep 2019
Print article
Image: Baxter International has acquired Cheetah Medical to expand their patient monitoring portfolio (Photo courtesy of Shutterstock).
Image: Baxter International has acquired Cheetah Medical to expand their patient monitoring portfolio (Photo courtesy of Shutterstock).
Baxter International Inc. (Deerfield, IL, USA), a global medical products company, has acquired Cheetah Medical (Boston, MA, USA), a provider of non-invasive hemodynamic monitoring technologies. Baxter offers a wide portfolio of critical care, nutrition, renal, hospital and surgical products across more than 100 countries. Cheetah Medical is a global provider of 100% non-invasive fluid management monitoring technologies, designed for use in critical care, operating room and emergency department settings.

The acquisition of Cheetah Medical is in line with Baxter’s commitment towards improving clinical outcomes with an established patient monitoring technology to better inform and guide clinicians’ treatment decisions. Cheetah Medical is a natural adjacency for Baxter, given Baxter’s presence in infusion systems and intravenous (IV) solutions, fluid management, and critical care and IV therapy.

The addition of Cheetah Medical will accelerate Baxter’s presence in the specialized patient monitoring space with key technology used to guide fluid management—a critical aspect of patient care—as too little or too much fluid can increase mortality and risk of complications. Cheetah Medical’s technology is helping to shift care away from a “one-size-fits-all” approach to fluid administration to one that is data-driven and tailored to individual patient needs. Cheetah Medical will provide Baxter with the company’s non-invasive hemodynamic monitoring systems, including its latest Starling SV system. These monitoring technologies provide dynamic measurements of fluid responsiveness, enabling clinicians to make more confident and informed treatment decisions regarding the proper amount of fluid required to maintain organ and tissue perfusion.

Through this integrated approach to medication delivery and patient monitoring, clinicians will be better able to manage patients with sepsis, acute kidney injury (AKI) and other critical conditions, as well as patients undergoing surgery. Cheetah Medical's technology will also serve as a foundational component of a novel platform of specialized patient monitoring technologies currently under development. This platform will join other Baxter devices and products—IV infusion pumps, IV fluids and medications—as part of an integrated system designed to aid and inform therapeutic decisions.

“The robust capabilities and innovative monitoring technologies we will gain with the acquisition of Cheetah Medical will be additional strategic growth drivers as we work to eliminate preventable harm and enable personalized therapy for hospitalized patients around the world,” said David Ferguson, general manager, Medication Delivery, Baxter. “We are enthusiastic about the opportunity to bring these products to more patients and clinicians and look forward to building upon Cheetah Medical’s expertise and technology to enhance our leadership in medication delivery and critical care.”

“Cheetah Medical brings a talented team with globally recognized experience in monitoring and fluid management,” added Ferguson. “We welcome the new employees who will help us grow our leadership in this space and join us in our mission to save and sustain lives.”

“We strongly believe in the power of our technology to help clinicians make more confident and informed treatment decisions in ways that can help improve patient outcomes and enhance healthcare efficiencies,” said Chris Hutchison, president and chief executive officer, Cheetah Medical. “Becoming part of Baxter will enable us to continue to invest in clinical and commercial initiatives on a global basis, which will help ensure that the right therapy gets to the right patients at the right time.”

Related Links:
Baxter International
Cheetah Medical


Print article
Mayo Medical Laboratories

Channels

Copyright © 2000-2019 Globetech Media. All rights reserved.